Compare SPRC & XAIR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | SPRC | XAIR |
|---|---|---|
| Founded | 2004 | 2011 |
| Country | Israel | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Medical/Dental Instruments |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 2.7M | 3.0M |
| IPO Year | 2014 | 2015 |
| Metric | SPRC | XAIR |
|---|---|---|
| Price | $1.10 | $2.30 |
| Analyst Decision | | Buy |
| Analyst Count | 0 | 2 |
| Target Price | N/A | ★ $20.00 |
| AVG Volume (30 Days) | ★ 715.6K | 57.1K |
| Earning Date | 11-20-2026 | 11-09-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $7,679,000.00 |
| Revenue This Year | $7,708.85 | $4.23 |
| Revenue Next Year | $73.22 | $108.84 |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | ★ 107.26 |
| 52 Week Low | $0.46 | $0.33 |
| 52 Week High | $15.79 | $8.19 |
| Indicator | SPRC | XAIR |
|---|---|---|
| Relative Strength Index (RSI) | 14.88 | 36.57 |
| Support Level | $0.52 | $2.05 |
| Resistance Level | $5.46 | $3.30 |
| Average True Range (ATR) | 0.49 | 0.19 |
| MACD | -0.25 | 0.05 |
| Stochastic Oscillator | 0.24 | 19.48 |
SciSparc Ltd is a specialty clinical stage pharmaceutical company. It is engaged in developing several immunotherapy products and it owns patents in the immunotherapy field. It is focused on creating and enhancing a portfolio of technologies and assets based on cannabinoid pharmaceuticals. The company has two operating reportable segments; development of drugs based on cannabinoid molecules to be approved by an official regulatory authority (the company's operation); and online sales of a various range of hemp-based products including hemp gummies, hemp oil capsules, hemp gel, hemp cream, detox pills, height pills, antibacterial creams, and anti-aging creams, among other beauty and hair treatment products that are all manufactured in the United States.
Beyond Air Inc a commercial-stage medical device and biopharmaceutical company developing a platform of nitric oxide (NO) generators and delivery systems (the LungFit platform) capable of generating NO from ambient air. Its segments are Beyond Air, Beyond Cancer, and NeuroNos. The company generates majority of revenue from Beyond Air. It has developed the Beyond Air NO generator and delivery system which it call LungFit, a novel and precise delivery system that uses NO generated from ambient air with a novel NO generator, the ionizer. Its product and technology includes LungFitPH.